Griffith Liang, MD
Pulmonary Disease · Spokane, WANPI 1891737748
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,980 of the $12,723 with a category attached, or 62.7%. 26 manufacturers reported payments, led by Intuitive Surgical at 31.0% of the total. Reporting peaked in 2024 at $6,243 and has fallen 69.3% since, to $1,914 in 2025. Among pulmonary disease clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 378 payments — averaging $33.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- AstraZeneca$2K
- GSK$1K
- Covidien LP$931
- United Therapeutics Corporation$742
- Boehringer Ingelheim$737
- plus $3K from 20 others
What the payments were for
- Travel & lodging$2,01516%
- Food & beverage$7,98063%
- Education$2,72821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $3,945 |
| AstraZeneca | 68 | $1,928 |
| GSK | 101 | $1,053 |
| Covidien LP | 16 | $931 |
| United Therapeutics Corporation | 32 | $742 |
| Boehringer Ingelheim | 24 | $737 |
| Electromed, Inc. | 10 | $567 |
| Sanofi | 18 | $369 |
| Actelion Pharmaceuticals US, Inc. | 11 | $286 |
| Verona Pharma, Inc. | 8 | $253 |
| Grifols USA, LLC | 9 | $209 |
| Baxter Healthcare | 10 | $206 |
| Merck | 6 | $170 |
| Regeneron Healthcare Solutions, Inc. | 6 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $164 |
| Genentech USA, Inc. | 9 | $161 |
| Amgen | 7 | $148 |
| Mylan Specialty L.p. | 7 | $137 |
| Insmed, Inc. | 4 | $124 |
| Philips North America LLC | 6 | $100 |
| Vifor Pharma, Inc. | 5 | $88 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Pfizer | 1 | $73 |
| Advanced Respiratory, Inc | 2 | $38 |
| Viatris Specialty LLC | 2 | $34 |
| Tactile Systems Technology Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,818
- TEZSPIRE$690
- FASENRA$690
- superDimension$552
- AIRSUPRA$538
- BREZTRI$532
- SMARTVEST$272
- SYMBICORT$152
- OFEV$125
- Ohtuvayre$125
How this compares
$12,723 in reported general payments places this provider in the 90th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 854 | $706,344 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 339 | $307,796 |
| Spiriva RespimatTiotropium Bromide | 222 | $164,943 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 202 | $140,034 |
| Breo ElliptaFluticasone/Vilanterol | 162 | $82,055 |
| Advair HfaFluticasone Propion/Salmeterol | 100 | $54,093 |
| SymbicortBudesonide/Formoterol Fumarate | 107 | $45,961 |
| Spiriva HandihalerTiotropium Bromide | 59 | $42,548 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 73 | $40,941 |
| DuleraMometasone/Formoterol | 61 | $34,773 |
| Incruse ElliptaUmeclidinium Bromide | 75 | $34,056 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 192 | $32,149 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 664 | $25,515 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $17,077 |
| EliquisApixaban | 24 | $16,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,053 | $871,0191,186 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Daliresp | $1,928 | $371,363479 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $737 | $322,054449 claims |
| MerckDulera | $170 | $34,77361 claims |
| PfizerEliquis | $73 | $16,18824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 275 pulmonary disease providers in Washington.
Other pulmonary disease in Spokane
- Jiten PatelSpokane$200K
- Fatima AjazSpokane$6K
- Benjamin ArthursSpokane$6K
- Harshwant GroverSpokane$6K
- Bryan AndersonSpokane$4K
- Jed GordenSeattle$236K
- Dominique PepperOlympia$212K
- Oneil BainsSeattle$156K
- Ganesh RaghuSeattle$147K
- Nicholas WyshamVancouver$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.